Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Genetics

Who is Most at Risk for Developing GNE Myopathy?

At a Glance

GNE myopathy can affect anyone globally, but the risk is highest for individuals of Persian Jewish, Japanese, and Indian descent due to historical founder mutations. Because it is an autosomal recessive condition, a person must inherit the mutated gene from both parents to develop the disease.

In this answer

4 sections

01

What is a Founder Mutation?

02

Communities with High-Risk Founder Mutations

03

Global Risk and Expanding Awareness

04

What This Means for Your Family

GNE myopathy can affect individuals of any ethnic background worldwide, but the risk is significantly higher for people of Persian Jewish, Japanese, and certain Indian ancestries [1][2]. While the condition is extremely rare on a global scale—estimated to affect only 1 to 9 out of every million people [3][4]—it appears much more frequently in these specific populations due to historical genetic patterns known as founder mutations [2][5].

What is a Founder Mutation?

To understand why certain groups are more at risk, it helps to look at how genetic traits are passed down. A founder mutation is a specific change in a gene (a mutation) that originated in a single ancestor many generations ago [5][6].

When a small group of individuals becomes isolated—either by geography or by cultural practices like marrying exclusively within their own religion or community—their genetic pool remains closed [7]. Over centuries, if one of the original “founders” of that community carried a rare genetic mutation, that mutation can become quite common among their descendants [8][9].

Because GNE myopathy is an autosomal recessive disorder, a person must inherit two mutated copies of the GNE gene (one from each parent) to develop the disease [10][11]. In closely knit communities with a founder mutation, it is far more likely that both parents will unknowingly carry the same mutation, increasing the chances of passing the condition to their children [2][12].

Communities with High-Risk Founder Mutations

While researchers have identified over 150 different mutations in the GNE gene worldwide, specific founder mutations are heavily linked to three primary ethnic groups [3][13]. You may see older names for GNE myopathy in your medical charts depending on when and where your family was diagnosed, but they all refer to the exact same condition.

  • Persian Jewish Ancestry: Historically referred to as “Hereditary Inclusion Body Myopathy” (HIBM), the condition is deeply tied to this community. Individuals of Persian Jewish descent have a high rate of a specific GNE mutation known as M743T [14]. You may sometimes see this listed on older genetic reports as M712T due to historical updates in genetic mapping.
  • Japanese Ancestry: In Japan, the condition was originally described as “Nonaka myopathy” or “Distal Myopathy with Rimmed Vacuoles” (DMRV). The D225V mutation is recognized as a prominent founder mutation in this population [15][16].
  • Indian Ancestry: GNE myopathy is increasingly recognized in the Indian subcontinent. The p.Val727Met (or V727M) mutation is a major founder mutation here, particularly noted in specific regions such as Gujarat [2][17]. Another mutation (p.Ile618Thr) is more frequently seen in patients from Rajasthan [18].

Global Risk and Expanding Awareness

Although the risk is highest in the groups mentioned above, anyone can develop GNE myopathy. As genetic testing becomes more advanced, the disease is being diagnosed in diverse populations globally, including in China, Turkey, South Korea, and Pakistan [19][20][21].

If you belong to one of the high-risk communities, the diagnostic process can actually be simpler and more cost-effective. Doctors can perform targeted genetic screening to look for the specific founder mutation known to affect your ethnic group before searching the entire gene [5][22]. However, many neurologists today opt to use comprehensive neuromuscular gene panels that check for many mutations at once, which helps rule out other conditions with similar symptoms simultaneously [23].

What This Means for Your Family

Because GNE myopathy is genetic, understanding the risk for your family members is crucial [10]:

  • Your Siblings: If you have the condition, it means both of your parents were healthy carriers. Because of this, each of your full siblings has a 25% chance of also having the disease, a 50% chance of being a carrier, and a 25% chance of being neither [10][24].
  • Your Children: If you have GNE myopathy, you will pass one mutated gene to all of your children, meaning they will absolutely be carriers. However, they will only develop the disease if your partner is also a carrier and passes down a second mutated gene [11][10].

Because learning about genetic risk can be complex and emotionally heavy, it is highly recommended to speak with a genetic counselor. They can help you understand your specific lab results, guide your family through the testing process, and discuss the implications for future generations.

Common questions in this guide

Why is GNE myopathy more common in certain ethnic groups?
GNE myopathy is more common in people of Persian Jewish, Japanese, and Indian descent due to founder mutations. These are specific genetic changes that originated in a single ancestor and became more frequent within close-knit or geographically isolated communities over generations.
How is GNE myopathy inherited?
GNE myopathy is an autosomal recessive disorder. This means a person must inherit two mutated copies of the GNE gene, one from each parent, in order to develop the disease.
If I have GNE myopathy, will my children get it?
If you have GNE myopathy, you will pass one mutated gene to all your children, making them carriers. They will only develop the actual disease if your partner is also a carrier and passes down a second mutated gene.
What are my siblings' chances of having GNE myopathy if I am diagnosed?
If you have the condition, it means both your parents are carriers. Because of this, each of your full siblings has a 25% chance of having the disease, a 50% chance of being a carrier, and a 25% chance of not carrying the mutation at all.
Can I get GNE myopathy if I do not have Persian Jewish, Japanese, or Indian ancestry?
No, anyone can develop GNE myopathy regardless of their ethnic background. While the risk is significantly higher in specific populations, advanced genetic testing has diagnosed the disease in diverse populations globally.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my ethnic background, should we start with targeted screening for a specific founder mutation, or use a comprehensive neuromuscular gene panel?
  2. 2.Can you refer my family to a genetic counselor to help us navigate testing for my siblings and children?
  3. 3.Could my symptoms be related to GNE myopathy even if I do not have Persian Jewish, Japanese, or Indian ancestry?
  4. 4.Are there specific signs my siblings should watch out for before they decide to undergo genetic testing?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Diet or Supplements Treat GNE Myopathy?Does GNE Myopathy Cause Sleep Apnea? Symptoms & TestingHow Fast Does GNE Myopathy Progress to a Wheelchair?Is Acenobel Available for GNE Myopathy Outside Japan?Is Exercise Safe for GNE Myopathy? Workout GuidelinesIs GNE Myopathy Hereditary?ManNAc vs. Acenobel: GNE Myopathy Therapies ComparedWhat is Quadriceps Sparing in GNE Myopathy?When Should I Get AFO Braces for GNE Myopathy Foot Drop?Why Does GNE Myopathy Cause Low Platelets?Why Is GNE Myopathy Often Misdiagnosed as CMT or sIBM?

References

References (24)
  1. 1

    [GNE myopathy].

    Urtizberea JA, Béhin A

    Medecine sciences : M/S 2015; (31 Spec No 3()):20-7 doi:10.1051/medsci/201531s306.

    PMID: 26546927
  2. 2

    Mutation Spectrum of GNE Myopathy in the Indian Sub-Continent.

    Bhattacharya S, Khadilkar SV, Nalini A, et al.

    Journal of neuromuscular diseases 2018; (5(1)):85-92 doi:10.3233/JND-170270.

    PMID: 29480215
  3. 3

    GNE Myopathy: Two Clusters with History and Several Founder Mutations.

    Argov Z, Mitrani Rosenbaum S

    Journal of neuromuscular diseases 2015; (2(s2)):S73-S76 doi:10.3233/JND-150087.

    PMID: 27858758
  4. 4

    Ultra-Orphan drug development for GNE Myopathy: A synthetic literature review and meta-analysis.

    Suzuki N, Mori-Yoshimura M, Nishino I, Aoki M

    Journal of neuromuscular diseases 2025; (12(2)):183-194 doi:10.1177/22143602241296226.

    PMID: 39973407
  5. 5

    Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.

    Siraj AK, Bu R, Iqbal K, et al.

    Human mutation 2019; (40(6)):729-733 doi:10.1002/humu.23736.

    PMID: 30825404
  6. 6

    Founder Effects in Hereditary Hemorrhagic Telangiectasia.

    Major T, Gindele R, Balogh G, et al.

    Journal of clinical medicine 2021; (10(8)) doi:10.3390/jcm10081682.

    PMID: 33919892
  7. 7

    Inbreeding tolerance as a pre-adapted trait for invasion success in the invasive ant Brachyponera chinensis.

    Eyer PA, Matsuura K, Vargo EL, et al.

    Molecular ecology 2018; (27(23)):4711-4724 doi:10.1111/mec.14910.

    PMID: 30368959
  8. 8

    Hints for panmixia in Scomberomorus commerson in Indian waters revealed by mitochondrial ATPase 6 and 8 genes.

    Vineesh N, Kathirvelpandian A, Divya PR, et al.

    Mitochondrial DNA. Part A, DNA mapping, sequencing, and analysis 2016; (27(4)):2822-4 doi:10.3109/19401736.2015.1053084.

    PMID: 26104155
  9. 9

    A founder effect in hemophilia A patients from Russian Ural region with a new p.(His634Arg) variant in F8 gene.

    Salomashkina VV, Pshenichnikova OS, Perina FG, Surin VL

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2022; (33(2)):124-129 doi:10.1097/MBC.0000000000001073.

    PMID: 34393174
  10. 10

    GNE Myopathy: Etiology, Diagnosis, and Therapeutic Challenges.

    Carrillo N, Malicdan MC, Huizing M

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2018; (15(4)):900-914 doi:10.1007/s13311-018-0671-y.

    PMID: 30338442
  11. 11

    Novel missense variants associated with GNE myopathy.

    Ranta-Aho J, Cetrangolo V, Bello L, et al.

    Neuromuscular disorders : NMD 2025; (56-57()):106258 doi:10.1016/j.nmd.2025.106258.

    PMID: 41232390
  12. 12

    A founder variant in the South Asian population leads to a high prevalence of FANCL Fanconi anemia cases in India.

    Donovan FX, Solanki A, Mori M, et al.

    Human mutation 2020; (41(1)):122-128 doi:10.1002/humu.23914.

    PMID: 31513304
  13. 13

    Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: First report from the GNE myopathy Disease Monitoring Program, registry portion.

    Pogoryelova O, Cammish P, Mansbach H, et al.

    Neuromuscular disorders : NMD 2018; (28(2)):158-168 doi:10.1016/j.nmd.2017.11.001.

    PMID: 29305133
  14. 14

    Upregulation of Hallmark Muscle Genes Protects GneM743T/M743T Mutated Knock-In Mice From Kidney and Muscle Phenotype.

    Benyamini H, Kling Y, Yakovlev L, et al.

    Journal of neuromuscular diseases 2020; (7(2)):119-136 doi:10.3233/JND-190461.

    PMID: 31985472
  15. 15

    Extra-muscular manifestations in GNE myopathy patients: A nationwide repository questionnaire survey in Japan.

    Yoshioka W, Shimizu R, Takahashi Y, et al.

    Clinical neurology and neurosurgery 2022; (212()):107057 doi:10.1016/j.clineuro.2021.107057.

    PMID: 34871992
  16. 16

    GNE myopathy: Don't sleep on the platelets.

    Beecher G, Liewluck T

    Muscle & nerve 2022; (65(3)):263-265 doi:10.1002/mus.27477.

    PMID: 34931325
  17. 17

    Dissecting role of founder mutation p.V727M in GNE in Indian HIBM cohort.

    Attri S, Sharma V, Kumar A, et al.

    Open medicine (Warsaw, Poland) 2021; (16(1)):1733-1744 doi:10.1515/med-2021-0391.

    PMID: 34825065
  18. 18

    The Inherited Neuromuscular Disorder GNE Myopathy: Research to Patient Care.

    Awasthi K, Arya R, Bhattacharya A, Bhattacharya S

    Neurology India 2019; (67(5)):1213-1219 doi:10.4103/0028-3886.271259.

    PMID: 31744945
  19. 19

    A recurrent GNE variant causing GNE myopathy in unrelated patients from Pakistan: a case series.

    Saleem S, Akbar F, Kirmani S, et al.

    Journal of medical case reports 2025; (19(1)):433 doi:10.1186/s13256-025-05524-4.

    PMID: 40885989
  20. 20

    Novel Mutation of the GNE Gene Presenting Atypical Mild Clinical Feature: A Korean Case Report.

    Choi YA, Park SH, Yi Y, Kim K

    Annals of rehabilitation medicine 2015; (39(3)):494-7 doi:10.5535/arm.2015.39.3.494.

    PMID: 26161358
  21. 21

    Clinical, pathological and genetic characteristics of GNE myopathy: a single-center observational study.

    Deng J, Wang N, Wu Y, et al.

    BMC musculoskeletal disorders 2025; (26(1)):1049 doi:10.1186/s12891-025-09282-8.

    PMID: 41239392
  22. 22

    Founder effects of the homogentisate 1,2-dioxygenase (HGD) gene in a gypsy population and mutation spectrum in the gene among alkaptonuria patients from India.

    Danda S, Mohan S, Devaraj P, et al.

    Clinical rheumatology 2020; (39(9)):2743-2749 doi:10.1007/s10067-020-05020-8.

    PMID: 32212000
  23. 23

    Identification of an Alu element-mediated deletion in the promoter region of GNE in siblings with GNE myopathy.

    Garland J, Stephen J, Class B, et al.

    Molecular genetics & genomic medicine 2017; (5(4)):410-417 doi:10.1002/mgg3.300.

    PMID: 28717665
  24. 24

    Analysis of the pathogenicity of novel GNE mutations and clinical, pathological, and genetic characteristics of GNE myopathy in Chinese population.

    Xing Y, Zhao L, Zhao R, et al.

    Orphanet journal of rare diseases 2025; (20(1)):161 doi:10.1186/s13023-025-03696-2.

    PMID: 40188109

This page explains genetic risk factors and inheritance patterns for GNE myopathy for educational purposes only. Always consult a genetic counselor or healthcare provider for personal risk assessment and family planning.

Get notified when new evidence is published on GNE myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.